Burkholderia pseudomallei and Melioidosis in Equines: Diagnosis in Tropical Regions

Etiology and Microbiological Characteristics

Burkholderia pseudomallei is a Gram-negative, motile, aerobic rod belonging to the family Burkholderiaceae. The organism is a saprophytic soil bacterium endemic to tropical and subtropical regions, particularly throughout Southeast Asia and northern Australia. It is the causative agent of melioidosis, a disease that affects a wide range of mammalian hosts including humans, sheep, goats, swine, and equids. In horses, melioidosis is a sporadic but often fatal infection that poses significant diagnostic challenges due to its clinical similarity to other suppurative and granulomatous conditions such as glanders (Burkholderia mallei), strangles (Streptococcus equi subsp. equi), and tuberculosis [1, 2].

The bacterium possesses a large genome (approximately 7.2 Mb) divided into two chromosomes, encoding an extensive array of virulence factors including type III and type VI secretion systems, capsular polysaccharides, lipopolysaccharides, and flagella. These factors enable B. pseudomallei to survive within phagocytes and resist complement-mediated lysis. The organism is intrinsically resistant to multiple antimicrobial classes, including aminoglycosides, macrolides, and first-generation cephalosporins, which complicates empirical therapy.

Epidemiology in Tropical Equine Populations

Melioidosis in horses occurs sporadically in endemic tropical regions. The primary reservoir is the environment; B. pseudomallei persists in soil and surface water, especially in rice paddies, clay soils, and areas with high rainfall. Horses become infected through percutaneous inoculation (e.g., via skin abrasions), inhalation of aerosolized bacteria, or ingestion of contaminated water or feed. Unlike in ruminants, where infection is often associated with wet seasons, equine cases may occur year-round in hyperendemic areas.

The true prevalence of equine melioidosis is poorly documented due to underdiagnosis and the lack of systematic surveillance. Serological surveys in parts of Thailand and northern Australia have reported antibody prevalences ranging from 5% to 15% in horse populations, but active clinical disease is rare. The disease is considered an occupational risk for horses in tropical farming systems, particularly those kept on pasture with access to mud wallows.

Host factors influencing susceptibility include immunosuppression, concurrent infections, and stress. There is no evidence of age or breed predilection, but foals may be more vulnerable due to immature immune responses.

Clinical Signs and Pathophysiology

Equine melioidosis presents in three main clinical forms: acute septicemic, chronic suppurative, and subclinical latent. The incubation period is variable, ranging from a few days to several months.

Acute Septicemic Form

This form is characterized by sudden onset of high fever (39.5 degrees C to 41.5 degrees C), depression, anorexia, tachypnea, and tachycardia. Progressing rapidly, horses develop septic shock, disseminated intravascular coagulation, and death within 24 to 72 hours. Postmortem findings typically include diffuse hemorrhagic lymphadenitis, splenomegaly, and multiple microabscesses in the liver, spleen, lungs, and kidneys.

Chronic Suppurative Form

The chronic form is more commonly observed and can mimic glanders. Clinical signs include:

• Intermittent pyrexia
• Weight loss and emaciation
• Chronic cough and nasal discharge (often purulent)
• Subcutaneous abscesses, particularly along the ventral abdomen and pectoral region
• Lymphangitis and enlargement of submandibular and prescapular lymph nodes, which may ulcerate and drain
• Lameness due to septic arthritis or osteomyelitis
• Neurological signs if the central nervous system is involved (rare)

Subclinical Latent Form

Infected horses may harbor B. pseudomallei in lymphoid tissues without overt signs. Latent infections can reactivate during periods of stress, parturition, or immunosuppressive therapy, leading to the clinical expression of disease. This latent carrier state has implications for disease control and movement of horses from endemic to nonendemic regions.

Pathology and Gross Lesions

Necropsy of horses with chronic melioidosis reveals caseous or purulent abscesses in the lungs, liver, spleen, kidneys, and lymph nodes. Abscesses may range from 1 mm to several centimeters in diameter and are often encapsulated. The lungs frequently show nodular lesions with central necrosis, similar to tuberculous granulomas. Histologically, these abscesses consist of a central core of necrotic debris and degenerate neutrophils surrounded by epithelioid macrophages, lymphocytes, and a fibrous capsule. Intracellular bacteria can be visualized with modified Wright stains (e.g., Giemsa) or specific immunohistochemistry.

In the septicemic form, lesions are more diffuse, with petechial hemorrhages, edema, and acute inflammatory infiltrates in multiple organs. The spleen is often enlarged and friable, and the liver may exhibit miliary necrotic foci.

Diagnostic Approaches

Diagnosing Burkholderia pseudomallei melioidosis in equines requires a high index of clinical suspicion, especially in tropical regions where other pyogenic diseases are common. A combination of culture-based, serological, and molecular methods is recommended. The diagnostic workflow is summarized in Figure 1.

Conventional Culture and Isolation

Definitive diagnosis relies on isolation of B. pseudomallei from clinical specimens. Samples include abscess aspirates, nasal swabs, blood, urine, synovial fluid, and tissue biopsies. The organism grows on standard bacteriological media (e.g., blood agar, MacConkey agar) under aerobic conditions at 37 degrees C. Colony morphology is variable: after 24 to 48 hours, colonies appear small, cream-colored, and slightly rough; after 3 to 5 days, they develop a wrinkled, metallic aspect characteristic of B. pseudomallei.

Selective media such as Ashdown's agar (containing gentamicin and crystal violet) enhance recovery from contaminated specimens. A positive culture is typically preliminary identified based on Gram stain (small Gram-negative rods with bipolar staining), oxidase positivity, resistance to gentamicin, and typical colony morphology.

Biochemical confirmation can be performed using commercial identification panels, but these may misidentify B. pseudomallei as Burkholderia cepacia or other species. MALDI-TOF mass spectrometry provides rapid and reliable identification if the spectral library includes B. pseudomallei.

Serological Testing

Serological assays are useful for supporting diagnosis, especially in chronic cases where culture is negative. The indirect hemagglutination assay (IHA) detects antibodies against B. pseudomallei lipopolysaccharide. A single titer of 1:40 or greater in a clinically compatible case is considered presumptive evidence, but false positives occur due to cross-reactivity with B. mallei and other environmental Burkholderia species.

Enzyme-linked immunosorbent assays (ELISAs) targeting specific antigens such as the capsular polysaccharide or the recombinant O-polysaccharide have been developed for human use but are not commercially validated for equine sera. In-house assays may be available at reference laboratories. Serology cannot distinguish active infection from past exposure.

Molecular Diagnostics

Polymerase chain reaction (PCR) targeting conserved genes such as wcb (capsular biosynthesis cluster) or the type III secretion system (TTSS1) offers a rapid and sensitive alternative to culture. Real-time PCR assays with fluorescent probes (e.g., TaqMan) can detect B. pseudomallei DNA directly from clinical specimens within 2 to 3 hours. Sensitivity is high for abscess aspirates and tissue biopsies but lower for blood and nasal swabs, especially if bacterial load is low.

Loop-mediated isothermal amplification (LAMP) assays have also been developed for field-deployable diagnosis in resource-limited tropical settings. LAMP operates at a constant temperature (60 degrees C to 65 degrees C) and requires only a simple heat block, making it suitable for regional veterinary diagnostic laboratories.

Diagnostic Algorithm

Figure 1 presents a decision tree for equine melioidosis diagnosis in tropical regions.

flowchart TD
    A["Equine patient with compatible clinical signs (fever, abscesses, lymphangitis, cough) in tropical region"], > B["Collect clinical samples: abscess aspirate, blood, nasal swab, tissue"]
    B, > C{"Gram-negative rods with bipolar staining?"}
    C, >|Yes| D["Culture on selective media (Ashdown's agar) and non-selective media"]
    C, >|No| E["Consider other diagnoses (glanders, strangles, tuberculosis)"]
    D, > F{"Colony morphology suggestive of B. pseudomallei?"}
    F, >|Yes| G["Confirm by MALDI-TOF or PCR targeting TTSS1"] 
    F, >|No| H["Biochemical identification; if inconclusive, perform PCR"]
    G, > I["Positive culture confirmed: diagnosis of melioidosis"]
    H, > J{"PCR positive?"}
    J, >|Yes| I
    J, >|No| K["Serology (IHA titer >= 1:40)"]
    K, > L{"Titer positive?"}
    L, >|Yes| M["Presumptive diagnosis; repeat culture and PCR if possible"]
    L, >|No| N["Melioidosis unlikely; investigate alternative causes"]

Figure 1. Diagnostic algorithm for equine melioidosis in tropical regions.

Differential Diagnoses

Melioidosis must be differentiated from:

• Glanders (Burkholderia mallei): Clinical presentation nearly identical; definitive distinction requires molecular identification or specific serological tests (e.g., complement fixation test or ELISA for B. mallei).
• Strangles (Streptococcus equi subsp. equi): Primarily affects young horses; characterized by purulent lymphadenitis; organism is Gram-positive.
• Tuberculosis (Mycobacterium bovis): Chronic weight loss, cough, and granulomatous lesions; acid-fast staining and culture on Lowenstein-Jensen media differentiate.
• Abscesses due to other pyogenic bacteria: Rhodococcus equi (foals), Staphylococcus aureus, Escherichia coli, or Actinobacillus spp. Culture and Gram stain are essential.

Treatment and Antimicrobial Susceptibility

Treatment of equine melioidosis is challenging due to intrinsic bacterial resistance and the tendency for relapse. The recommended human therapeutic regimen consists of an intensive phase (ceftazidime or meropenem for 2 to 4 weeks) followed by an eradication phase (trimethoprim-sulfamethoxazole for 12 to 20 weeks). This approach has been extrapolated to horses with limited published evidence.

Dosages used in equine practice include ceftazidime (50 to 100 mg/kg intravenously every 8 hours) for acute cases, followed by oral trimethoprim-sulfamethoxazole (30 mg/kg every 12 hours) for extended therapy. However, gastrointestinal side effects and the risk of antimicrobial-induced diarrhea in horses require careful monitoring. Doxycycline and amoxicillin-clavulanate are alternative options but are less reliably bactericidal.

Surgical drainage of accessible abscesses is an important adjunctive measure. Long-term therapy (minimum 8 to 12 weeks) is necessary to prevent recrudescence. Antimicrobial susceptibility testing should be performed on all isolates to guide treatment.

Control and Prevention

Control of melioidosis in equine populations relies on reducing environmental exposure and early detection of cases. In endemic tropical regions, management measures include:

• Avoiding turnout in flooded paddocks or areas with known soil contamination.
• Providing clean drinking water from treated sources.
• Promptly cleaning and disinfecting skin wounds.
• Isolating suspect clinical cases and testing in-contact horses.

There is no licensed vaccine for melioidosis in any species. Euthanasia is recommended for chronically infected horses in nonendemic areas to prevent spread and zoonotic risk, although human-to-human transmission is rare. The zoonotic potential of B. pseudomallei underscores the need for barrier precautions (gloves, masks, eye protection) when handling infected animals and their exudates.

Conclusions

Equine melioidosis is an underrecognized bacterial disease in tropical regions that closely mimics other suppurative and granulomatous infections. Accurate diagnosis requires a combination of culture, molecular detection, and serology, ideally guided by a standardized algorithm. The intrinsic antibiotic resistance and capacity for latent infection make treatment protracted, and prognosis is guarded. Increased veterinary awareness and access to affordable diagnostic tools are needed to improve detection and management of this serious equine infection.

References

[1] Wiersinga WJ, van der Poll T, White NJ, Day NP, Peacock SJ. Melioidosis: insights into the pathogenicity of Burkholderia pseudomallei. Nature Reviews Microbiology. 2006;4(4):272-282.

[2] Cheng AC, Currie BJ. Melioidosis: epidemiology, pathophysiology, and management. Clinical Microbiology Reviews. 2005;18(2):383-416.